Advertisement
Advertisement
Julie Zhang
Reporter, Business
Julie Zhang joined SCMP in 2025 as a business reporter. She was formerly with China Daily Hong Kong Edition for over five years, covering corporate earnings, IPOs, financial regulations, ESG, cryptocurrency and property markets. Her reporting garnered multiple Hong Kong News Awards and Hang Seng University's Business Journalism Award.
Julie Zhang joined SCMP in 2025 as a business reporter. She was formerly with China Daily Hong Kong Edition for over five years, covering corporate earnings, IPOs, financial regulations, ESG, cryptocurrency and property markets. Her reporting garnered multiple Hong Kong News Awards and Hang Seng University's Business Journalism Award.
Areas of Expertise:
Corporate finance, IPOSLanguages Spoken:
Cantonese, English, Mandarin
Slumping profits at Shandong Xinhua Pharmaceutical have dragged the shares to about HK$7 in December 2025 from HK$15.62 in December 2022.
The cost of a single monkey exceeds the average annual salary in China and approaches a pandemic-era spike amid growth in drug licensing deals.
More than 200,000 people file complaints as UBS SDIC’s attempted remedy for sudden change of fund’s price benchmark falls flat with some.
The three companies will be added to the gauge after the market close on March 6, while car dealer Zhongsheng Group will be removed.
Advertisement
The Tsinghua Holdings arm, however, will raise US$800 million via a private share placement on Shenzhen exchange.
A wave of government-linked investment is boosting Chinese AI drug makers, underscoring Beijing’s drive to build its own biotech ecosystem.
Privately owned Distinct Healthcare plans to open a clinic in Dubai, while TCM group Gushengtang eyes 50 centres in Southeast Asia.
An index tracking Stock Connect buying of 40 mainland drug firms gains 9 per cent in a week as China’s industry heft grows.
Three of China’s stock exchanges have relaxed fundraising time thresholds on listed tech companies as Beijing pushes for self-reliance.
Drug makers in China are performing cutting-edge research and licensing products to global giants after a 10-year government push supercharged the industry.
The deal comes as Chinese novel drug makers are having more say in how their new medicines are developed with global partners.
Mainland China’s issuers will still dominate city’s IPO market, executive says, but US and Southeast Asian companies are also joining in.
Some retreat to the sidelines as another fund suspends new investments and futures plunge, while others remain determined to buy the dip.
Fifth consecutive sell-out at Sai Sha development shows recovery gathering pace, with analysts forecasting further price increases ahead.
AI and genetics are creating a ‘seismic shift’ in the pharmaceutical business, experts on Asian Financial Forum panel say.
Global institutional investors have built up sizeable positions in firms including Innovent, 3SBio, WuXi Biologics, Jiangsu Hengrui, Akeso and BeOne.
Latest example of Chinese drug maker acquiring equity in overseas partner shows they are becoming true development partners, analysts say.
While US biotech firms increase use of Chinese clinical data, Chinese firms need US counterparts for monetisation, investor and scientist says.
The agreement will help SF Holding expand its international businesses, according to the Shenzhen-based company.
SciNeuro’s anti-amyloid programme is one of the firm’s key strategic research and development priorities to target the brain disease.
Foreign, local firms fight for market share as number of overweight or obese adults could top 630 million by 2050, from 400 million in 2021.
Over the past year, 34 innovation and technology, life and health science companies set up or expanded their operations in Hong Kong.
Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.
Fosun and Huadong biotech labs eye feline obesity drugs as owners weigh cuteness against health risks.
Chinese rivals fill out the rest of the top five, while US bank Morgan Stanley comes in sixth.
Multi-year partnership with France’s Servier will use Insilico’s AI platform to explore novel cancer drugs.
A wave of China out-licensing deals is feeding a biotech comeback in Hong Kong, where IPOs and follow-on placements are surging.
US firm, backed by Fosun and Tencent, expands research base in China as it develops an AI-powered drug-discovery tool.
A burst of overseas licensing pacts is spotlighting China’s biotech sector, as Jacobio, Coherent Biopharma and Harbour BioMed land deals.
